338 related articles for article (PubMed ID: 22786770)
21. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
22. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
Hofer J; Janecke AR; Zimmerhackl LB; Riedl M; Rosales A; Giner T; Cortina G; Haindl CJ; Petzelberger B; Pawlik M; Jeller V; Vester U; Gadner B; van Husen M; Moritz ML; Würzner R; Jungraithmayr T;
Clin J Am Soc Nephrol; 2013 Mar; 8(3):407-15. PubMed ID: 23243267
[TBL] [Abstract][Full Text] [Related]
23. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
24. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
25. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications.
Cieślik P; Hrycek A
Autoimmunity; 2012 Mar; 45(2):119-28. PubMed ID: 21988562
[TBL] [Abstract][Full Text] [Related]
26. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
Valoti E; Alberti M; Iatropoulos P; Piras R; Mele C; Breno M; Cremaschi A; Bresin E; Donadelli R; Alizzi S; Amoroso A; Benigni A; Remuzzi G; Noris M
Front Immunol; 2019; 10():853. PubMed ID: 31118930
[TBL] [Abstract][Full Text] [Related]
27. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.
Foltyn Zadura A; Zipfel PF; Bokarewa MI; Sturfelt G; Jönsen A; Nilsson SC; Hillarp A; Saxne T; Trouw LA; Blom AM
Arthritis Res Ther; 2012 Aug; 14(4):R185. PubMed ID: 22894814
[TBL] [Abstract][Full Text] [Related]
28. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
Strobel S; Hoyer PF; Mache CJ; Sulyok E; Liu WS; Richter H; Oppermann M; Zipfel PF; Józsi M
Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
[TBL] [Abstract][Full Text] [Related]
29. Human pentraxin 3 binds to the complement regulator c4b-binding protein.
Braunschweig A; Józsi M
PLoS One; 2011; 6(8):e23991. PubMed ID: 21915248
[TBL] [Abstract][Full Text] [Related]
30. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation.
Csincsi ÁI; Kopp A; Zöldi M; Bánlaki Z; Uzonyi B; Hebecker M; Caesar JJ; Pickering MC; Daigo K; Hamakubo T; Lea SM; Goicoechea de Jorge E; Józsi M
J Immunol; 2015 May; 194(10):4963-73. PubMed ID: 25855355
[TBL] [Abstract][Full Text] [Related]
31. M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules.
Gout E; Moriscot C; Doni A; Dumestre-Pérard C; Lacroix M; Pérard J; Schoehn G; Mantovani A; Arlaud GJ; Thielens NM
J Immunol; 2011 May; 186(10):5815-22. PubMed ID: 21490156
[TBL] [Abstract][Full Text] [Related]
32. The long pentraxin PTX3 in vascular pathology.
Mantovani A; Garlanda C; Bottazzi B; Peri G; Doni A; Martinez de la Torre Y; Latini R
Vascul Pharmacol; 2006 Nov; 45(5):326-30. PubMed ID: 17023219
[TBL] [Abstract][Full Text] [Related]
33. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation.
Deban L; Jarva H; Lehtinen MJ; Bottazzi B; Bastone A; Doni A; Jokiranta TS; Mantovani A; Meri S
J Immunol; 2008 Dec; 181(12):8433-40. PubMed ID: 19050261
[TBL] [Abstract][Full Text] [Related]
34. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
Hirt-Minkowski P; Dickenmann M; Schifferli JA
Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.
Nauta AJ; Bottazzi B; Mantovani A; Salvatori G; Kishore U; Schwaeble WJ; Gingras AR; Tzima S; Vivanco F; Egido J; Tijsma O; Hack EC; Daha MR; Roos A
Eur J Immunol; 2003 Feb; 33(2):465-73. PubMed ID: 12645945
[TBL] [Abstract][Full Text] [Related]
36. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
[TBL] [Abstract][Full Text] [Related]
37. FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation.
Csincsi ÁI; Szabó Z; Bánlaki Z; Uzonyi B; Cserhalmi M; Kárpáti É; Tortajada A; Caesar JJE; Prohászka Z; Jokiranta TS; Lea SM; Rodríguez de Córdoba S; Józsi M
J Immunol; 2017 Jul; 199(1):292-303. PubMed ID: 28533443
[TBL] [Abstract][Full Text] [Related]
38. Dihydrolipoamide dehydrogenase of Pseudomonas aeruginosa is a surface-exposed immune evasion protein that binds three members of the factor H family and plasminogen.
Hallström T; Mörgelin M; Barthel D; Raguse M; Kunert A; Hoffmann R; Skerka C; Zipfel PF
J Immunol; 2012 Nov; 189(10):4939-50. PubMed ID: 23071278
[TBL] [Abstract][Full Text] [Related]
39. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
Blanc C; Roumenina LT; Ashraf Y; Hyvärinen S; Sethi SK; Ranchin B; Niaudet P; Loirat C; Gulati A; Bagga A; Fridman WH; Sautès-Fridman C; Jokiranta TS; Frémeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2012 Oct; 189(7):3528-37. PubMed ID: 22922817
[TBL] [Abstract][Full Text] [Related]
40. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation.
Inforzato A; Peri G; Doni A; Garlanda C; Mantovani A; Bastone A; Carpentieri A; Amoresano A; Pucci P; Roos A; Daha MR; Vincenti S; Gallo G; Carminati P; De Santis R; Salvatori G
Biochemistry; 2006 Sep; 45(38):11540-51. PubMed ID: 16981714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
